## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>President’s Message</td>
<td>3</td>
</tr>
<tr>
<td>AMP Strategic Plan</td>
<td>4</td>
</tr>
<tr>
<td>Mission Statement</td>
<td>4</td>
</tr>
<tr>
<td>Vision Statement</td>
<td>5</td>
</tr>
<tr>
<td>Core Principles</td>
<td>5</td>
</tr>
<tr>
<td>2019 Board of Directors and Committee Chairs</td>
<td>6</td>
</tr>
<tr>
<td>Affiliations</td>
<td>7</td>
</tr>
<tr>
<td>Organizational Relationships</td>
<td>7</td>
</tr>
<tr>
<td>Advocacy and Clinical Practice</td>
<td>8</td>
</tr>
<tr>
<td>Membership and Annual Meeting Overview</td>
<td>9</td>
</tr>
<tr>
<td>International Education Initiatives</td>
<td>10</td>
</tr>
<tr>
<td>Financial Statement</td>
<td>11</td>
</tr>
</tbody>
</table>
Message

FROM THE PRESIDENT

Dear Colleagues,

This year, AMP celebrated its 25th anniversary at our annual meeting in Baltimore, Maryland. What an adventure it has been! From assembling at small workshops to gathering in bustling Expo Halls around the globe, AMP has truly grown into an international, diverse, and dynamic community.

AMP brings together molecular pathologists, clinical laboratorians, basic and translational scientists, technologists and trainees. Together, we advance the clinical practice, science, and excellence of our field to provide the highest quality health care for patients. Now more than ever, molecular testing is at the forefront of modern medicine.

AMP develops clinical practice guidelines and shares ground-breaking research in our foremost academic publication, *The Journal of Molecular Diagnostics*. We advocate for patients at our places of work, as well as in the halls of government and regulatory agencies. We collaborate to create a comprehensive catalog of educational offerings, and we exchange key knowledge at our professional meetings.

In 2019, our Board of Directors conducted extensive visioning exercises to chart AMP’s future, approving programs that will enhance the value of AMP membership for many years to come. In addition, AMP hosted its second Global Congress on Molecular Pathology in May in Hong Kong.

Serving as your President has been a true honor. I look forward to our community’s continued successes.

Sincerely,

Victoria M. Pratt, PhD, FACMG
Indiana University School of Medicine
AMP’S STRATEGIC PLAN IS DYNAMIC.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP’s Mission, Vision, and Core Principles, which were updated this year.

MISSION STATEMENT

The ASSOCIATION FOR MOLECULAR PATHOLOGY is a not-for-profit scientific society that advances the CLINICAL PRACTICE, SCIENCE, and EXCELLENCE of molecular and genomic laboratory medicine through EDUCATION, INNOVATION, and ADVOCACY to enable highest quality health care.
This year, AMP’s Board of Directors worked hard on evaluating our mission and vision. The field of molecular diagnostics is ever evolving and this important exercise lead to a decision to introduce a new vision for the association.

**VISION STATEMENT**

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** provides global expertise in molecular testing that drives patient care.

**CORE PRINCIPLES**

- Quality Health Care Through **EXCELLENCE** in Clinical Molecular Testing
- Fostering the **GLOBAL COMMUNITY** of Molecular Pathology Professionals
- **COLLABORATION** to Advance Molecular Pathology
- **ADVOCACY** that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- **INNOVATION** to Transform Patient Care
PRESIDENT
Victoria M. Pratt, PhD
Indiana University Medical Center

PRESIDENT-ELECT
Karen Weck, MD
University of North Carolina

INFECTION DISEASES SUBDIVISION CHAIR
Frederick S. Nolte, PhD
Medical University of South Carolina

INFORMATICS SUBDIVISION CHAIR
Somak Roy, MD
University of Pittsburgh Medical Center

SOLID TUMORS SUBDIVISION CHAIR
Roger D. Klein, MD, JD
University of Washington Medical Center

INVITED GUEST
Rami Mahfouz, MD, MPH
American University of Beirut Medical Center

EXECUTIVE DIRECTOR
Mary Steele Williams, MNA, MT(ASCP)SM, CAE

PRESIDENT-ELECT
Karen Weck, MD
University of North Carolina

SECRETARY-TREASURER
Daniel E. Sabath, MD, PhD
University of Washington Medical Center

PAST PRESIDENT
Kojo S. J. Elenitoba-Johnson, MD
University of Pennsylvania, Perelman School of Medicine

PAST PRESIDENT
Kojo S. J. Elenitoba-Johnson, MD
University of Pennsylvania, Perelman School of Medicine

SECRETARY-TREASURER
Daniel E. Sabath, MD, PhD
University of Washington Medical Center

PAST PRESIDENT
Kojo S. J. Elenitoba-Johnson, MD
University of Pennsylvania, Perelman School of Medicine

SECRETARY-TREASURER
Daniel E. Sabath, MD, PhD
University of Washington Medical Center

CLINICAL PRACTICE COMMITTEE CHAIR
Dan Jones, MD, PhD
The Ohio State University

ECONOMIC AFFAIRS COMMITTEE CHAIR
Samuel K. Caughron, MD
MAWD Pathology Group, PA

MEMBERSHIP AFFAIRS COMMITTEE CHAIR
Midhat S. Farooqi, MD, PhD
University of Missouri-Kansas City School of Medicine

PROFESSIONAL RELATIONS COMMITTEE CHAIR
Jordan Laser, MD
Northwell Health

PROGRAM COMMITTEE CHAIR
Neal Lindeman, MD
Brigham & Women’s Hospital

PUBLICATION & COMMUNICATION COMMITTEE CHAIR
Paul G. Rothberg, PhD
University of Rochester Medical Center

TRAINING & EDUCATION COMMITTEE CHAIR
Cecilia Ching Sze Yeung, MD
Fred Hutchinson Cancer Research Center

HEMATOPATHOLOGY SUBDIVISION CHAIR
Annette Kim, MD, PhD
Brigham and Women’s Hospital

GENETICS SUBDIVISION CHAIR
Thomas W. Prior, PhD
Case Western University

INFECTION DISEASES SUBDIVISION CHAIR
Frederick S. Nolte, PhD
Medical University of South Carolina

INFORMATICS SUBDIVISION CHAIR
Somak Roy, MD
University of Pittsburgh Medical Center

SOLID TUMORS SUBDIVISION CHAIR
Roger D. Klein, MD, JD
Roger D Klein, MD, JD

INVITED GUEST
Rami Mahfouz, MD, MPH
American University of Beirut Medical Center

EXECUTIVE DIRECTOR
Mary Steele Williams, MNA, MT(ASCP)SM, CAE
Collaborations

INTERNATIONAL AFFILIATES

The Hong Kong Society for Molecular Diagnostic Sciences (2013)
The Molecular Pathology Association of India (2013)
The Korean Society for Laboratory Medicine (2013)
The German Society of Pathology (2015)
Brazilian Society of Clinical Pathology and Laboratory Medicine (2017)
The Italian Society of Pathology and Translational Medicine (2017)
American University of Beirut Medical Center (2018)
Middle East Molecular Biology Sources (2019)

ORGANIZATIONAL RELATIONSHIPS

AMP maintains MEMBERSHIP in the following organizations:
• The Pathology Roundtable
• Cancer Leadership Council (CLC)
• Federation of American Societies for Experimental Biology (FASEB)
• Global Alliance for Genomic Medicine
• Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
• Intersociety Pathology Council (IPC)
• Personalized Medicine Coalition (PMC)

AMP maintains RELATIONSHIPS with many organizations, including but not limited to:
• Representative to ASCO CancerLinQ Steering Committee
• Cooperating Society of the American Board of Pathology (ABP)
• Steering Committee, NIST Genome in A Bottle Consortium
• Associate Member of the Intersociety Council for Pathology Information (ICPI)
• Sponsor of the National Academies Roundtable on Genomics and Precision Health
• Representatives to FNIH Biomarkers Consortium Steering Committees
• Representative to the College of American Pathology (CAP) Pathology Coding Caucus (PCC)
• Representative to the CAP Molecular Oncology Committee
AMP ADVOCATES for excellence in molecular testing in clinical laboratories. We advance the field and practice of molecular pathology by representing the membership to the federal agencies and members of Congress to inform and influence public policy. AMP’s clinical and scientific affairs initiatives aim to transform patient care through innovation. INNOVATION.

ADVOCACY

In 2019, around 60 members participated in AMP’s Advocacy Day on Capitol Hill, meeting with policymakers to discuss regulation, reimbursement, and advancing patient care. In addition, AMP led and participated in numerous joint advocacy initiatives, hosted two “lunch and learns” with patient advocates, and submitted 35 ADVOCACY COMMENT LETTERS & POSITION STATEMENTS on issues such as:

- National Coverage Determination for Next Generation Sequencing for Advanced Cancer Patients
- Draft Bills on Oversight of Laboratory Developed Testing Procedures
- Local Coverage Determinations for Molecular Pathology Procedures
- Protecting Access to Medicare Act (PAMA) Data Reporting and Implementation
- Updated AMP Position Statement on Consumer Genomic Testing
- Best Practices for Clinical Pharmacogenomic Testing
- Potential concerning updates to Section 101 of the Patent Act

INNOVATION & IMPROVED PATIENT CARE

In 2019, over 165 MEMBER VOLUNTEERS worked on behalf of AMP to foster excellence in clinical practice and patient care, serving on AMP-led working groups or as AMP representatives to external collaborative projects and committees. The vast majority of AMP-led CPC Working Groups have representation from other organizations, to include the most recent AMP report:

Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists
Engaging

MEMBERSHIP & MEETINGS

AMP ended the year with continued membership growth for the 13th straight year, rising from 2,514 in 2018 to 2,522 in 2019. Indicators suggest that growth will continue for the coming years. AMP members can be found in 57 COUNTRIES.

Attendance continued to be strong at the 2019 ANNUAL MEETING. We welcomed 2,150 attendees and over 170 companies. In addition, we welcomed nearly 500 attendees and 30 exhibiting companies at AMP GLOBAL, our first meeting in Asia.

<table>
<thead>
<tr>
<th>YEAR</th>
<th>LOCATION</th>
<th>ATTENDEES</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>GAYLORD TEXAN, TX</td>
<td>1,343</td>
</tr>
<tr>
<td>2012</td>
<td>LONG BEACH, CA</td>
<td>1,674</td>
</tr>
<tr>
<td>2013</td>
<td>PHOENIX, AZ</td>
<td>1,720</td>
</tr>
<tr>
<td>2014</td>
<td>WASHINGTON, DC</td>
<td>1,944</td>
</tr>
<tr>
<td>2015</td>
<td>AUSTIN, TX</td>
<td>2,084</td>
</tr>
<tr>
<td>2016</td>
<td>CHARLOTTE, NC</td>
<td>2,022</td>
</tr>
<tr>
<td>2017</td>
<td>SALT LAKE CITY, UT</td>
<td>2,201</td>
</tr>
<tr>
<td>2018</td>
<td>SAN ANTONIO, TX</td>
<td>2,106</td>
</tr>
<tr>
<td>2019</td>
<td>BALTIMORE, MD</td>
<td>2,150</td>
</tr>
</tbody>
</table>

AMP MEMBERS BY DEGREE:

- PhD 900 (35.7%)
- MD 1104 (43.8%)
- Other 518 (20.5%)

Recipients of the Jeffrey A. Kant Leadership Award gathered at the 2019 Annual Meeting & Expo.

2019 AMP Global Organizing Committee in Hong Kong.
AMP’s educational initiatives continue to reach a global audience. In 2019, AMP hosted its second GLOBAL CONGRESS ON MOLECULAR PATHOLOGY meeting in HONG KONG. AMP invited speakers also presented at three AMP-affiliate society conferences in INDIA, KOREA, and BRAZIL. In addition, the International Affairs Committee hosted a luncheon for international attendees at the AMP 2019 Annual Meeting, entitled “Certification in Molecular Pathology outside the USA”.

Two new grant-supported AMP Education webinar series were launched in 2019: An additional two-part series on Tumor Mutational Burden and a three-part series on PARP Inhibitors. Each series was recorded and is available on AMP’s Online Learning Platform, AMPED™, through 2021. Other supported content (Advancing Patient Care in NSCLC: Breaking Down Barriers and the 2018 TMB webinar series) is also available. All registration and continuing education credit for these grant-supported online offerings are available at no charge.

The AMP learning management system, AMPED™, has more than 200 hours of cutting-edge molecular pathology content delivered by experts in the field. To learn more, visit educate.amp.org
AMP’s fiscal footing is solid, allowing it to dedicate significant resources to each of its strategic initiatives.

<table>
<thead>
<tr>
<th>STRATEGIC INITIATIVE</th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy</td>
<td>$(612,500)</td>
<td>$(490,772)</td>
<td>$(437,181)</td>
</tr>
<tr>
<td>Communications &amp; Outreach</td>
<td>$(149,155)</td>
<td>$(125,071)</td>
<td>$(193,658)</td>
</tr>
<tr>
<td>Education</td>
<td>1,832,607</td>
<td>2,021,273</td>
<td>1,932,749</td>
</tr>
<tr>
<td>Innovation &amp; Improved Patient Care</td>
<td>$(290,091)</td>
<td>$(250,296)</td>
<td>$(288,701)</td>
</tr>
<tr>
<td>Membership &amp; Management Services</td>
<td>$(76,388)</td>
<td>$(220,128)</td>
<td>$(208,213)</td>
</tr>
</tbody>
</table>

**EXCESS REVENUE OVER EXPENSES**

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>$704,474</strong></td>
<td><strong>$935,006</strong></td>
<td><strong>$804,996</strong></td>
</tr>
</tbody>
</table>